GSK and Daiichi Sankyo enter into strategic alliance to establish a Vaccine Joint Venture in Japan
March 2, 2012
GSK Japan and Daiichi Sankyo announce that GSK Biologicals, GSK Japan and Daiichi Sankyo have agreed to enter into a strategic alliance in vaccines business and will form a Vaccine Joint Venture in Japan. Ｔｈｅ Joint Venture will be named Japan Vaccine Co., Ltd. (hereinafter, JV)． GSK and Daiichi Sankyo will invest equally to JV.
１． Background and Significance
Recently due to the progress of science and medicine, efforts towards disease prevention are increasing significantly. In Japan however, many vaccines which have effectively contributed to diseases prevention in other advanced countries are not used. To improve the situation, the Vaccine Industry Vision proposed by MHLW in March 2007 talks about the need to strengthen the vaccine industry and in recent years many new vaccines are being introduced showing substantial change in the environment for vaccines. Under such environment, it has been decided to create a new vaccine company combining
the strength of both partners, namely GSK, with its extensive global development know-how, rich pipeline, most advanced technology and recent contributions to the Japanese vaccine market environment, coupled with Daiichi Sankyo's development know-how in Japan, domestic production capability, and the domestic experience of sales and logistics, to meet the medical needs of society by delivering vaccines quickly. JV will be responsible for late stage development, marketing and sales of prophylactic vaccines and will aim to protect Japanese people of all ages from children to the elderly from infections.
- Contribute to improving access to vaccines in Japan.
- Introduce new vaccines for which vaccination is recommended overseas and increase product line-up.
- Create better, more convenient combination vaccines by bringing together the technologies and products of parent companies.
- Provide evidence based information and ensure stable supply of vaccines to realizewide distribution and high vaccination rate
２． Outline of JV
JV will inherit the development and commercial rights for prophylactic vaccines from both parent companies and will be responsible for clinical development, marketing and sales in Japan. At start up, JV will market vaccines marketed by GSK and Daiichi Sankyo and expand the business as new vaccines in the development pipeline are approved.
Name Japan Vaccine Co., Ltd.
Founded April 2, 2012
July 2, 2012
Head Office Tokyo, JAPAN
Representative Chairman & Co-CEO: Toshihiro Ishikiriyama
President & Co-CEO: Akira Nagano
Capital 100 million yen
Investment % GSK 50％、Daiichi Sankyo 50％
Business Development, import and sales of prophylactic vaccines
Main Products Cervarix, Rotarix、Seasonal flu vaccine, , mumps
vaccine, DTP vaccine, MR vaccine etc.
Employee About 200 （120 M Reps）
３． About GSK
GlaxoSmithKline Biologicals - (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development - both in the prophylactic and therapeutic fields. Headquartered in Belgium, GSK Biologicals has 14 manufacturing sites strategically positioned around the globe. In 2010, GSK Biologicals distributed 1.43 billion doses of vaccines to 179 countries in both the developed and the developing world.
About GSK Japan
Name GlaxoSmithKline K.K.
Representative President, Philippe Fauchet
Founded August 18, 1953
Address Sendagaya, Shibuya-ku, Tokyo JAPAN
Capital 2067 million yen
Business Pharmaceuticals, Consumer healthcare products,
Employees About 3500
４． About Daiichi Sankyo
Name Daiichi Sankyo Co., Ltd.
Representative President, Joji Nakayama
Founded September 28, 2005
Address Honcho, Chuo-ku, Tokyo JAPAN
Capital 50 billion yen
Employees 31,570 （consolidated）
Corporate Communications Department
Daiichi Sankyo Co. Ltd.
Corporate Communications Department